SCHEMBL24285848

SCHEMBL24285848

Nc1nc2ccc(-c3cnc4[nH]ccc4c3)cn2c1C(=O)C1CNC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 2/20 0.47
▸ RIPK1 Q13546 4/20 0.46
▸ MAP4K1 Q92918 1/20 0.42
▸ CDK8 P49336 6/20 0.42
▸ CDK7 P50613 2/20 0.42
▸ CCNT1 O60563 1/20 0.42
▸ CCND1 P24385 1/20 0.42
▸ CCNC P24863 1/20 0.42
▸ CDK9 P50750 1/20 0.42
▸ CCNH P51946 1/20 0.42
▸ MNAT1 P51948 1/20 0.42
▸ CDK6 Q00534 1/20 0.42
▸ ABL1 P00519 1/20 0.41
▸ PLK4 O00444 2/20 0.40
▸ MAP4K4 O95819 2/20 0.40
▸ ROS1 P08922 2/20 0.40
▸ MARK3 P27448 2/20 0.40
▸ FLT4 P35916 2/20 0.40
▸ KDR P35968 2/20 0.40
▸ CLK2 P49760 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29537003 1.00 LRRK2 (0.47) LRRK2RIPK1MAP4K1CDK8CDK7
SCHEMBL24285969 0.94 LRRK2 (0.45) LRRK2RIPK1MAP4K1CDK8CDK7
SCHEMBL29538200 0.94 LRRK2 (0.45) LRRK2RIPK1MAP4K1CDK8CDK7
SCHEMBL29537401 0.86 LRRK2 (0.59) LRRK2RIPK1MAP4K1CDK8CDK7
SCHEMBL24285977 0.86 LRRK2 (0.59) LRRK2RIPK1MAP4K1CDK8CDK7
SCHEMBL24285965 0.81 PRKCA (0.35) LRRK2ABL1JAK2
SCHEMBL29537655 0.81 PRKCA (0.35) LRRK2ABL1JAK2
SCHEMBL24285989 0.81 CDK2 (0.34) LRRK2CDK8CCNCABL1CDK2
SCHEMBL29537364 0.81 CDK2 (0.34) LRRK2CDK8CCNCABL1CDK2
SCHEMBL24285984 0.80 RIPK1 (0.47) LRRK2RIPK1MAP4K1CDK8CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4214207-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1st Biotherapeutics, Inc. (KR) 2023-07-26 — — EP claimed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1ST Biotherapeutics, Inc. (KR) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds NLRP3, NLRP1, KCNJ2 LRRK2 538/4885RIPK1 1112/4885MAP4K1 235/4885
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS NLRP3, NLRP1, KCNJ2 LRRK2 538/4885RIPK1 1112/4885MAP4K1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback